Computational drug discovery

Myers S, Baker A . Drug discovery - an operating model for a new era. Nat Biotechnol 2001; 19: 727–30.

Moses H 3rd, Dorsey ER, Matheson DH, Thier SO . Financial anatomy of biomedical research. JAMA 2005; 294: 1333–42.

Lahana R . How many leads from HTS? Drug Discov Today 1999; 4: 447–8.

Lobanov V . Using artificial neural networks to drive virtual screening of combinatorial libraries. Drug Discov Today Biosilico 2004; 2: 149–56.

Shekhar C . In silico pharmacology: computer-aided methods could transform drug development. Chem Biol 2008; 15: 413–4.

Song CM, Lim SJ, Tong JC . Recent advances in computer-aided drug design. Brief Bioinform 2009; 10: 579–91.

Jorgensen WL . The many roles of computation in drug discovery. Science 2004; 303: 1813–8.

Xiang M, Cao Y, Fan W, Chen L, Mo Y . Computer-aided drug design: lead discovery and optimization. Comb Chem High Throughput Screen 2012; 15: 328–37.

Zhang S . Computer-aided drug discovery and development. Methods Mol Biol 2011; 716: 23–38.

Tan JJ, Cong XJ, Hu LM, Wang CX, Jia L, Liang XJ . Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov Today 2010; 15: 186–97.

Chen L, Morrow JK, Tran HT, Phatak SS, Du-Cuny L, Zhang S . From laptop to benchtop to bedside: structure-based drug design on protein targets. Curr Pharm Des 2012; 18: 1217–39.

Acharya C, Coop A, Polli JE, Mackerell AD Jr . Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des 2011; 7: 10–22.

Wang F, Liu DX, Wang HY, Luo C, Zheng MY, Liu H, et al. Computational screening for active compounds targeting protein sequences: methodology and experimental validation. J Chem Inf Model 2011; 51: 2821–8.

Tang Y, Zhu WL, Chen KX, Jiang HL . New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery. Drug Discov Today Technol 2006; 3: 307–13.

Jorgensen WL . Efficient drug lead discovery and optimization. Acc Chem Res 2009; 42: 724–33.

Hajduk PJ, Huth JR, Tse C . Predicting protein druggability. Drug Discov Today 2005; 10: 1675–82.

Huan CM, Elmets CA, Tan DC, Li F, Yusuf N . Proteomics reveals that proteins expressed during the early stage of Bacillus anthracis infection are potential targets for the development of vaccines and drugs. Genomics Proteomics Bioinformatics 2004; 2: 143–51.

Li HL, Gao ZT, Kang L, Zhang HL, Yang K, Yu KQ, et al. TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res 2006; 34: W219–24.

Ewing TJ, Makino S, Skillman AG, Kuntz ID . DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 2001; 15: 411–28.

Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE . A geometric approach to macromolecule-ligand interactions. J Mol Biol 1982; 161: 269–88.

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010; 9: 203–14.

Chen X, Ji ZL, Chen YZ . TTD: Therapeutic Target Database. Nucleic Acids Res 2002; 30: 412–5.

Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34: D668–72.

Gao ZT, Li HL, Zhang HL, Liu XF, Kang L, Luo XM, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008; 9: 104.

Liu XF, Ouyang SS, Yu BA, Liu YB, Huang K, Gong JY, et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res 2010; 38: W609–14.

Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008; 36: D901–6.

Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK . BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007; 35: D198–201.

Wang R, Fang X, Lu Y, Wang S . The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J Med Chem 2004; 47: 2977–80.

Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47: 1739–49.

Jain AN . Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 2003; 46: 499–511.

Li HL, Zhang HL, Zheng MY, Luo J, Kang L, Liu XF, et al. An effective docking strategy for virtual screening based on multi-objective optimization algorithm. BMC Bioinformatics 2009; 10: 58.

Li HL, Li CL, Gui CS, Luo XM, Chen KX, Shen JH, et al. GAsDock: a new approach for rapid flexible docking based on an improved multi-population genetic algorithm. Bioorg Med Chem Lett 2004; 14: 4671–6.

Bissantz C, Folkers G, Rognan D . Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem 2000; 43: 4759–67.

Kang L, Li HL, Jiang HL, Wang XC . An improved adaptive genetic algorithm for protein-ligand docking. J Comput Aided Mol Des 2009; 23: 1–12.

Liu XF, Bai F, Ouyang SS, Wang XC, Li HL, Jiang HL . Cyndi: a multi-objective evolution algorithm based method for bioactive molecular conformational generation. BMC Bioinformatics 2009; 10: 101.

Shoichet BK, Leach AR, Kuntz ID . Ligand solvation in molecular docking. Proteins 1999; 34: 4–16.

Bai F, Liu XF, Li JB, Zhang HY, Jiang HL, Wang XC, et al. Bioactive conformational generation of small molecules: a comparative analysis between force-field and multiple empirical criteria based methods. BMC Bioinformatics 2010; 11: 545.

Gohlke H, Hendlich M, Klebe G . Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol 2000; 295: 337–56.

Mitchell JBO, Laskowski RA, Alex A, Thornton JM . BLEEP - Potential of mean force describing protein-ligand interactions: I. Generating potential. J Comput Chem 1999; 20: 1165–76.

Muegge I, Martin YC . A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J Med Chem 1999; 42: 791–804.

Sippl MJ . Boltzmann's principle, knowledge-based mean fields and protein folding. An approach to the computational determination of protein structures. J Comput Aided Mol Des 1993; 7: 473–501.

Xue MZ, Zheng MY, Xiong B, Li YL, Jiang HL, Shen JK . Knowledge-based scoring functions in drug design. 1. Developing a target-specific method for kinase-ligand interactions. J Chem Inf Model 2010; 50: 1378–86.

Muegge I . PMF scoring revisited. J Med Chem 2006; 49: 5895–902.

Zhao XY, Liu XF, Wang YY, Chen Z, Kang L, Zhang HL, et al. An improved PMF scoring function for universally predicting the interactions of a ligand with protein, DNA, and RNA. J Chem Inf Model 2008; 48: 1438–47.

Shen QC, Xiong B, Zheng MY, Luo XM, Luo C, Liu XA, et al. Knowledge-based scoring functions in drug design: 2. Can the knowledge base be enriched? J Chem Inf Model 2011; 51: 386–97.

Muchmore SW, Edmunds JJ, Stewart KD, Hajduk PJ . Cheminformatic tools for medicinal chemists. J Med Chem 2010; 53: 4830–41.

Maldonado AG, Doucet JP, Petitjean M, Fan BT . Molecular similarity and diversity in chemoinformatics: from theory to applications. Mol Divers 2006; 10: 39–79.

Liu XF, Jiang HL, Li HL . SHAFTS: a hybrid approach for 3D molecular similarity calculation 1. Method and assessment of virtual screening. J Chem Inf Model 2011; 51: 2372–85.

Cai CQ, Gong JY, Liu XF, Jiang HL, Gao DQ, Li HL . A novel, customizable and optimizable parameter method using spherical harmonics for molecular shape similarity comparisons. J Mol Model 2012; 18: 1597–610.

Drewry DH, Young SS . Approaches to the design of combinatorial libraries. Chemometr Intell Lab Syst 1999; 48: 1–20.

Chen G, Zheng SX, Luo XM, Shen JH, Zhu WL, Liu H, et al. Focused combinatorial library design based on structural diversity, druglikeness and binding affinity score. J Comb Chem 2005; 7: 398–406.

Liu TQ, Lin YM, Wen X, Jorissen RN, Gilson MK . BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007; 35: D198–201.

Cai JH, Han C, Hu TC, Zhang J, Wu DL, Wang FD, et al. Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: Reverse docking, enzymatic assay, and X-ray crystallography validation. Protein Sci 2006; 15: 2071–81.

Surh Y . Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 1999; 428: 305–27.

Jeong CH, Bode AM, Pugliese A, Cho YY, Kim HG, Shim JH, et al. [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res 2009; 69: 5584–91.

Spiegel S, Milstien S . Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4: 397–407.

Chun J, Rosen H . Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr Pharm Des 2006; 12: 161–71.

Schwab SR, Cyster JG . Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007; 8: 1295–301.

Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009; 325: 1254–7.

Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010; 465: 1084–8.

Ridley AJ . Rho family proteins: coordinating cell responses. Trends Cell Biol 2001; 11: 471–7.

Sander EE, Collard JG . Rho-like GTPases: Their role in epithelial cell-cell adhesion and invasion. Eur J Cancer 1999; 35: 1302–8.

Wheeler AP, Ridley AJ . Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 2004; 301: 43–9.

Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004; 47: 1750–9.

Deng J, Feng EG, Ma S, Zhang Y, Liu XF, Li HL, et al. Design and synthesis of small molecule RhoA inhibitors: a new promising therapy for cardiovascular diseases? J Med Chem 2011; 54: 4508–22.

Randhawa R, Cohen P . The role of the insulin-like growth factor system in prenatal growth. Mol Genet Metab 2005; 86: 84–90.

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE . The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215–44.

Liu XF, Xie H, Luo C, Tong LJ, Wang Y, Peng T, et al. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. J Med Chem 2010; 53: 2661–5.

Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV, et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell 2009; 35: 511–22.

Lu WQ, Liu XF, Cao XW, Xue MZ, Liu KD, Zhao ZJ, et al. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration. J Med Chem 2011; 54: 3564–74.

Dornan J, Taylor P, Walkinshaw MD . Structures of immunophilins and their ligand complexes. Curr Top in Med Chem 2003; 3: 1392–409.

Galat A . Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr Top Med Chem 2003; 3: 1315–47.

Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL . Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807–15.

Zuo XJ, Matsumura Y, Prehn J, Saito R, Marchevesky A, Matloff J, et al. Cytokine gene expression in rejecting and tolerant rat lung allograft models: analysis by RT-PCR. Transpl Immunol 1995; 3: 151–61.

Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP . Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993; 73: 1067–78.

Luo C, Luo HB, Zheng SX, Gui CS, Yue LD, Yu CY, et al. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem Biophys Res Commun 2004; 321: 557–65.

Curtis M, Nikolopoulos SN, Turner CE . Actopaxin is phosphorylated during mitosis and is a substrate for cyclin B1/cdc2 kinase. Biochem J 2002; 363: 233–42.

Dawson TM, Steiner JP, Lyons WE, Fotuhi M, Blue M, Snyder SH . The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience 1994; 62: 569–80.

Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W, et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res 2007; 67: 3654–62.

Li J, Chen J, Gui CS, Zhang L, Qin Y, Xu Q, et al. Discovering novel chemical inhibitors of human cyclophilin A: virtual screening, synthesis, and bioassay. Bioorg Med Chem 2006; 14: 2209–24.

Li J, Zhang J, Chen J, Luo XM, Zhu WL, Shen JH, et al. Strategy for discovering chemical inhibitors of human cyclophilin a: focused library design, virtual screening, chemical synthesis and bioassay. J Comb Chem 2006; 8: 326–37.

Singh S, Malik BK, Sharma DK . Molecular drug targets and structure based drug design: A holistic approach. Bioinformation 2006; 1: 314–20.

Kumar N, Hendriks BS, Janes KA, de Graaf D, Lauffenburger DA . Applying computational modeling to drug discovery and development. Drug Discov Today 2006; 11: 806–11.

Kubinyi H . Drug research: myths, hype and reality. Nat Rev Drug Discov 2003; 2: 665–8.

Schuffenhauer A, Jacoby E . Annotating and mining the ligand-target chemogenomics knowledge space. Drug Discov Today Biosilico 2004; 2: 190–200.

Kopec KK, Bozyczko-Coyne D, Williams M . Target identification and validation in drug discovery: the role of proteomics. Biochem Pharmacol 2005; 69: 1133–9.

Paul N, Kellenberger E, Bret G, Muller P, Rognan D . Recovering the true targets of specific ligands by virtual screening of the protein data bank. Proteins 2004; 54: 671–80.

Chen YZ, Ung CY . Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. J Mol Graph Model 2001; 20: 199–218.

Shen JH, Xu XY, Cheng F, Liu H, Luo XM, Shen JK, et al. Virtual screening on natural products for discovering active compounds and target information. Curr Med Chem 2003; 10: 2327–42.

Stockwell BR . Exploring biology with small organic molecules. Nature 2004; 432: 846–54.